Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) annual activity report 2025

Minutes of the Management Board meeting: 17-18 December 2025

Human medicines European public assessment report (EPAR): Yeytuo, lenacapavir, Date of authorisation: 25/08/2025, Revision: 1, Status: Authorised

European Medicines Agency (EMA) stakeholder relations management framework

Human medicines European public assessment report (EPAR): Adenuric, febuxostat, Date of authorisation: 21/04/2008, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Remsima, infliximab, Date of authorisation: 10/09/2013, Revision: 45, Status: Authorised

Human medicines European public assessment report (EPAR): Sunlenca, lenacapavir, Date of authorisation: 17/08/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Fluad Tetra, influenza vaccine (surface antigen, inactivated, adjuvanted), Date of authorisation: 20/05/2020, Revision: 10, Status: Withdrawn

Standard operating procedure for annual review of VeDDRA list to be used in EudraVigilance Veterinary

Human medicines European public assessment report (EPAR): Conexxence, denosumab, Date of authorisation: 18/07/2025, Revision: 1, Status: Authorised